-
1Academic Journal
Authors: T. E. Kolmakova, I. A. Alekseeva, N. A. Tmoyan, M. V. Ezhov, Т. Е. Колмакова, И. А. Алексеева, Н. А. Тмоян, М. В. Ежов
Source: Meditsinskiy sovet = Medical Council; № 5 (2024); 22-29 ; Медицинский Совет; № 5 (2024); 22-29 ; 2658-5790 ; 2079-701X
Subject Terms: эзетимиб, dyslipidemia, low-density lipoprotein cholesterol (LDL-C), target LDL-C level, atherosclerotic cardiovascular diseases, rosuvastatin, ezetimibe, Rosulip Plus, дислипидемия, холестерин липопротеидов низкой плотности (ХС ЛНП), целевой уровень ХС ЛНП, атеросклеротические сердечно-сосудистые заболевания, розувастатин
File Description: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/8218/7241; Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111–188. https://doi.org/10.1093/eurheartj/ehz455.; Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472. https://doi.org/10.1093/eurheartj/ehx144.; Кухарчук ВВ, Ежов МВ, Сергиенко ИВ, Арабидзе ГГ, Бубнова МГ, Балахонова ТВ и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020(1):7–42. Режим доступа: https://jad.noatero.ru/index.php/jad/article/view/274/271.; Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952. https://doi.org/10.1016/S0140-6736(04)17018-9.; Метельская ВА, Шальнова СА, Деев АД, Перова НВ, Гомыранова НВ, Литинская ОА и др. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов у жителей Российской Федерации (по данным исследования ЭССЕ-РФ). Профилактическая медицина. 2016;19(1):15–23. https://doi.org/10.17116/profmed201619115-23.; Мешков АН, Ершова АИ, Деев АИ, Метельская ВА, Жернакова ЮВ, Ротарь ОП и др. Распределение показателей липидного спектра у мужчин и женщин трудоспособного возраста в Российской Федерации: результаты исследования Эссе-РФ За 2012–2014 гг. Кардиоваскулярная терапия и профилактика. 2017;16(4):62–67. https://doi.org/10.15829/1728–8800–2017–4-62–67.; Концевая АВ, Баланова ЮА, Имаева АЭ, Худяков МБ, Карпов ОИ, Драпкина ОМ. Экономический ущерб от гиперхолестеринемии на популяционном уровне в Российской Федерации. Рациональная фармакотерапия в кардиологии. 2018;14(3):393–401. https://doi.org/10.20996/1819-6446-2018-14-3-393-401.; Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168–3209. https://doi.org/10.1016/j.jacc.2018.11.002.; Алексеева ИА, Колмакова ТЕ, Ежов МВ. Фиксированная комбинация «розувастатин + эзетимиб» – удобство, безопасность и эффективность. Медицинский совет. 2019;(16):21–26. https://doi.org/10.21518/2079-701X-2019-16-21-26.; Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, Turchin A. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526–534. https://doi.org/10.7326/0003-4819-158-7-201304020-00004.; Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028–3035. https://doi.org/10.1161/CIRCULATIONAHA.108.768986.; Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497. https://doi.org/10.1056/NEJMra050100.; Dykun I, Wiefhoff D, Totzeck M, Al-Rashid F, Jánosi RA, Rassaf T, Mahabadi AA. Disconcordance between ESC prevention guidelines and observed lipid profiles in patients with known coronary artery disease. Int J Cardiol Heart Vasc. 2019;22:73–77. https://doi.org/10.1016/j.ijcha.2018.12.004.; Presta V, Figliuzzi I, Miceli F, Coluccia R, Fogacci F, Cicero AFG, Ferrucci A et al. Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy. Atherosclerosis. 2019;285:40–48. https://doi.org/10.1016/j.atherosclerosis.2019.03.017.; Алексеева ИА, Ежов МВ. Особенности применения фиксированной комбинации розувастатина и эзетимиба для эффективной гиполипидемической терапии. Медицинский совет. 2020;(14):26–32. https://doi.org/10.21518/2079-701X-2020-14-26-32.; Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769–1818. https://doi.org/10.1093/eurheartj/ehr158.; Колмакова ТЕ, Алексеева ИА, Ежов МВ. Розувастатин как доступное средство для эффективной профилактики сердечно-сосудистых заболеваний. РМЖ. 2020;10:20–24. Режим доступа: https://www.rmj.ru/articles/kardiologiya/Rozuvastatin_kak_dostupnoe_sredstvo_dlya_effektivnoy_profilaktiki_serdechno-sosudistyh_zabolevaniy/#ixzz6nO976Jge.; Karlson BW, Wiklund O, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur Heart J Cardiovasc Pharmacother. 2016;2(4):212–217. https://doi.org/10.1093/ehjcvp/pvw006.; Hammersley D, Signy M. Ezetimibe: an update on its clinical usefulness in specific patient groups. Ther Adv Chronic Dis. 2017;8(1):4–11. https://doi.org/10.1177/2040622316672544.; Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415–427. https://doi.org/10.2147/VHRM.S33664.; Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239. https://doi.org/10.1161/01.CIR.0000133317.49796.0E.; Ouchi Y, Sasaki J, Arai H, Yokote K, Harada K, Katayama Y et al. Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial. Circulation. 2019;140(12):992–1003. https://doi.org/10.1161/CIRCULATIONAHA.118.039415.; Ambegaonkar BM, Tipping D, Polis AB, Tomassini JE, Tershakovec AM. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. Atherosclerosis. 2014;237:829–837. https://doi.org/10.1016/j.atherosclerosis.2014.10.105.; Gudzune KA, Monroe AK, Sharma R, Ranasinghe PD, Chelladurai Y, Robinson KA. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review. Ann Intern Med. 2014;160(7):468–476. https://doi.org/10.7326/M13-2526.; Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J et al. Lipidaltering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223(2):251–261. https://doi.org/10.1016/j.atherosclerosis.2012.02.016.; Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387–2397. https://doi.org/10.1056/NEJMoa1410489.; Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007;99(5):673–680. https://doi.org/10.1016/j.amjcard.2006.10.022.; Bays HE, Davidson MH, Massaad R, Flaim D, Lowe RS, Tershakovec AM, Jones-Burton C. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol. 2011;108(4):523–530. https://doi.org/10.1016/j.amjcard.2011.03.079.; Hong SJ, Jeong HS, Ahn JC, Cha DH, Won KH, Kim W et al. A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial. Clin Ther. 2018;40(2):226–241.e4. https://doi.org/10.1016/j.clinthera.2017.12.018.; Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400(10349):380–390. https://doi.org/10.1016/S0140-6736(22)00916-3.; Katzmann JL, Sorio-Vilela F, Dornstauder E, Fraas U, Smieszek T, Zappacosta S, Laufs U. Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C. Clin Res Cardiol. 2022;111(3):243–252. https://doi.org/10.1007/s00392-020-01740-8.; Lee SA, Kim W, Hong TJ, Ahn Y, Kim MH, Hong SJ et al . Effects of Fixed-dose Combination of Low-intensity Rosuvastatin and Ezetimibe Versus Moderateintensity Rosuvastatin Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia: A Randomized, Double-blind, Multicenter, Phase III Study. Clin Ther. 2021;43(9):1573–1589. https://doi.org/10.1016/j.clinthera.2021.07.016.; Obońska K, Kasprzak M, Tymosiak K, Fabiszak T, Krintus M, Kubica J. Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): A randomized, crossover study - preliminary results. Cardiol J. 2021;28(1):58–66. Available at: https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC8105047&blobtype=pdf.
-
2Academic Journal
Authors: I. A. Mazerkina, T. V. Bukatina, T. V. Aleksandrova, И. А. Мазеркина, Т. М. Букатина, Т. В. Александрова
Contributors: The study reported in this publication was carried out as part of publicly funded research project No. 056-00052- 23-00 and was supported by the Scientific Centre for Expert Evaluation of Medicinal Products (R&D public accounting No. 121021800098-4)., Работа выполнена в рамках государственного задания ФГБУ «НЦЭСМП» Минздрава России № 05600052-23-00 на проведение прикладных научных исследований (номер государственного учета НИР 121021800098-4)
Source: Safety and Risk of Pharmacotherapy; Том 11, № 3 (2023); 292-302 ; Безопасность и риск фармакотерапии; Том 11, № 3 (2023); 292-302 ; 2619-1164 ; 2312-7821
Subject Terms: безопасность лекарственных средств, dyslipidaemia, atherosclerosis, lipid-lowering therapy, statin intolerance, ezetimibe, low density lipoprotein cholesterol, safety of medicinal products, дислипидемия, атеросклероз, гиполипидемическая терапия, непереносимость статинов, эзетимиб, холестерин липопротеидов низкой плотности
File Description: application/pdf
Relation: https://www.risksafety.ru/jour/article/view/385/880; https://www.risksafety.ru/jour/article/downloadSuppFile/385/418; https://www.risksafety.ru/jour/article/downloadSuppFile/385/422; GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223–49. https://doi.org/10.1016/S0140-6736(20)30752-2; Kjekshus J, Pedersen TR. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1995;76(9):64C–8C. https://doi.org/10.1016/s0002-9149(99)80473-1; Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78. https://doi.org/10.1016/S0140-6736(05)67394-1; Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2(1):47–54. https://doi.org/10.1001/jamacardio.2016.4052; Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81. https://doi.org/10.1016/S0140-6736(10)61350-5; Ежов МВ, Кухарчук ВВ, Сергиенко ИВ, Алиева АС, Анциферов МБ, Аншелес АА и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):5471. https://doi.org/10.15829/1560-4071-2023-5471; Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. https://doi.org/10.1093/eurheartj/ehz455; Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):3168–209. https://doi.org/10.1016/j.jacc.2018.11.002; Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. 2021 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37(8):1129–50. https://doi.org/10.1016/j.cjca.2021.03.016; Buettner C, Davis RB, Leveille SG, Mittleman MA, Mukamal KJ. Prevalence of musculoskeletal pain and statin use. J Gen Intern Med. 2008;23(8):1182–6. https://doi.org/10.1007/s11606-008-0636-7; Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–410. https://doi.org/10.1016/j.jacc.2016.02.071; Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients — the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403– 14. https://doi.org/10.1007/s10557-005-5686-z; Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding statin use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15. https://doi.org/10.1016/j.jacl.2012.03.003; Tournadre A. Statins, myalgia, and rhabdomyolysis. Joint Bone Spine. 2020;87(1):37–42. https://doi.org/10.1016/j.jbspin.2019.01.018; Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009;32(10):1924–9. https://doi.org/10.2337/dc09-0738; Ma T, Tien L, Fang CL, Liou YS, Jong GP. Statins and new-onset diabetes: a retrospective longitudinal cohort study. Clin Ther. 2012;34(9):1977–83. https://doi.org/10.1016/j.clinthera.2012.08.004; Howard JP, Wood FA, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, et al. Side effect patterns in a crossover trial of statin, placebo, and no treatment. J Am Coll Cardiol. 2021;78(12):1210–22. https://doi.org/10.1016/j.jacc.2021.07.022; Herrett E, Williamson E, Brack K, Beaumont D, Perkins A, Thayne A, et al.; StatinWISE Trial Group. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ. 2021;372:n135. https://doi.org/10.1136/bmj.n135; Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, et al. ASCOT Investigators. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebocontrolled trial and its non-randomised non-blind extension phase. Lancet. 2017;389(10088):2473–81. https://doi.org/10.1016/S0140-6736(17)31075-9; Moon J, Cohen Sedgh R, Jackevicius CA. Examining the nocebo effect of statins through statin adverse events reported in the food and drug administration adverse event reporting system. Circ Cardiovasc Qual Outcomes. 2021;14(1):e007480. https://doi.org/10.1161/CIRCOUTCOMES.120.007480; Penson PE, Mancini GBJ, Toth PP, Martin SS, Watts GF, Sahebkar A, et al. Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group & International Lipid Expert Panel (ILEP). Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. J Cachexia Sarcopenia Muscle. 2018;9(6):1023–33. https://doi.org/10.1002/jcsm.12344; Леонова М.В. Эффекты ноцебо и друцебо в определении статин-индуцированных мышечных симптомов. Медицинский Совет. 2022;(17):136–42. Leonova MV. Effects of nocebo and drucebo in determining statin-induced muscle symptoms. Medical Council. 2022;(17):136–42 (In Russ.). https://doi.org/10.21518/2079-701X-2022-16-17-136-142; Talic S, Marquina C, Ofori-Asenso R, Petrova M, Liew D, Owen AJ, et al. Persistence and adherence to statin therapy: a retrospective cohort study using the Australian national pharmacy data. Cardiovasc Drugs Ther. 2022;36(5):867–77. https://doi.org/10.1007/s10557-021-07199-7; Wong ND, Young D, Zhao Y, Nguyen H, Caballes J, Khan I, Sanchez RJ. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011–2012. J Clin Lipidol. 2016;10(5):1109–18. https://doi.org/10.1016/j.jacl.2016.06.011; Rezende Macedo do Nascimento RC, Mueller T, Godman B, MacBride Stewart S, Hurding S, de Assis Acurcio F, et al. Real-world evaluation of the impact of statin intensity on adherence and persistence to therapy: a Scottish population-based study. Br J Clin Pharmacol. 2020;86(12):2349–61. https://doi.org/10.1111/bcp.14333; Hagen AN, Ariansen I, Hanssen TA, Lappegård KT, Eggen AE, Løchen ML, et al. Achievements of primary prevention targets in individuals with high risk of cardiovascular disease: an 8-year follow-up of the Tromsø study. Eur Heart J Open. 2022;2(5):oeac061. https://doi.org/10.1093/ehjopen/oeac061; Reiner Z. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis. 2014;24(10):1057–66. https://doi.org/10.1016/j.numecd.2014.05.009; Pinkosky SL, Groot PHE, Lalwani ND, Steinberg GR. Targeting ATP-citrate lyase in hyperlipidemia and metabolic disorders. Trends Mol Med. 2017;23(11):1047–63. https://doi.org/10.1016/j.molmed.2017.09.001; Pearce NJ, Yates JW, Berkhout TA, Jackson B, Tew D, Boyd H, et al. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem J. 1998;334(Pt 1):113–9. https://doi.org/10.1042/bj3340113; Burke AC, Telford DE, Huff MW. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 2019;30(1):1–9. https://doi.org/10.1097/MOL.0000000000000565; Pinkosky SL, Filippov S, Srivastava RA, Hanselman JC, Bradshaw CD, Hurley TR, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013;54(1):134–51. https://doi.org/10.1194/jlr.M030528; Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353–64. https://doi.org/10.1056/NEJMoa2215024; Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022–32. https://doi.org/10.1056/NEJMoa1803917; Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA. 2019;322(18):1780–8. https://doi.org/10.1001/jama.2019.16585; Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7):e011662. https://doi.org/10.1161/JAHA.118.011662; Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195–203. https://doi.org/10.1016/j.atherosclerosis.2018.06.002; Banach M, Duell PB, Gotto AM, Laufs U, Leiter LA, Mancini GBJ, et al. Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia. JAMA Cardiol. 2020;5(10):1124–35. https://doi.org/10.1001/jamacardio.2020.2314; Agarwala A, Quispe R, Goldberg AC, Michos ED. Bempedoic acid for heterozygous familial hypercholesterolemia: from bench to bedside. Drug Des Devel Ther. 2021;15:1955–63. https://doi.org/10.2147/DDDT.S251865; Ballantyne CM, Bays H, Catapano AL, Goldberg A, Ray KK, Saseen JJ. Role of bempedoic acid in clinical practice. Cardiovasc Drugs Ther. 2021;35(4):853–64. https://doi.org/10.1007/s10557-021-07147-5; Bays HE, Banach M, Catapano AL, Duell PB, Gotto AM, Laufs U, et al. Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials. J Clin Lipidol. 2020;14(5):649–59.e6. https://doi.org/10.1016/j.jacl.2020.08.009; Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy — European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–22. https://doi.org/10.1093/eurheartj/ehv043; Ray K, Bakris G, Banach M, Catapano A, Duell P, Mancini G, et al. Effect of bempedoic acid on uric acid and gout in 3621 patients with hypercholesterolemia: pooled analyses from phase 3 trials. Eur Heart J. 2020;41(Suppl 2):ehaa946.3001. https://doi.org/10.1093/ehjci/ehaa946.3001; Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force. JAMA. 2016;316(19):2008–24. https://doi.org/10.1001/jama.2015.15629; Sun H, Wu Y, Bian H, Yang H, Wang H, Meng X, et al. Function of uric acid transporters and their inhibitors in hyperuricaemia. Front Pharmacol. 2021;12:667753. https://doi.org/10.3389/fphar.2021.667753; Ruscica M, Sirtori CR, Carugo S, Banach M, Corsini A. Bempedoic acid: for whom and when. Curr Atheroscler Rep. 2022;24(10):791–801. https://doi.org/10.1007/s11883-022-01054-2; Elsby R, Hilgendorf C, Fenner K. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it’s not just about OATP1B1. Clin Pharmacol Ther. 2012;92(5):584–98. https://doi.org/10.1038/clpt.2012.163; Shitara Y. Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions. Drug Metab Pharmacokinet. 2011;26(3):220–7. https://doi.org/10.2133/dmpk.DMPK-10-RV-094; Jadhav SB, Crass RL, Chapel S, Kerschnitzki M, Sasiela WJ, Emery MG, et al. Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model. Eur Heart J Cardiovasc Pharmacother. 2022;8(6):578–86. https://doi.org/10.1093/ehjcvp/pvab064; Laakso M, Kuusisto J. Diabetes secondary to treatment with statins. Curr Diab Rep. 2017;17(2):10. https://doi.org/10.1007/s11892-017-0837-8; Шпагина ОВ, Бондаренко ИЗ, Колесникова ГС. Терапия статинами ассоциирована с повышением уровня ИРФ-1 у больных ИБС без сахарного диабета. Проблемы эндокринологии. 2018;64(4):200–7. https://doi.org/10.14341/probl8759; Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–85. https://doi.org/10.1007/s00125-017-4342-z; Zhao X, Ma X, Luo X, Shi Z, Deng Z, Jin Y, et al. Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials. BMC Pharmacol Toxicol. 2020;21(1):86. https://doi.org/10.1186/s40360-020-00463-w; Lin Y, Parco C, Karathanos A, Krieger T, Schulze V, Chernyak N, et al. Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis. BMJ Open. 2022;12(2):e048893. https://doi.org/10.1136/bmjopen-2021-048893; Sayed A, Shazly O, Slipczuk L, Krittanawong C, Baloch F, Virani SS. The clinical efficacy and safety of bempedoic acid in patients at elevated risk of cardiovascular disease: a meta-analysis of randomized clinical trials. Cardiovasc Drugs Ther. 2023 Jun 1. https://doi.org/10.1007/s10557-023-07474-9; Khan MU, Khan MZ, Munir MB, Balla S, Khan SU. Meta-analysis of the safety and efficacy of bempedoic acid. Am J Cardiol. 2020;131:130–2. https://doi.org/10.1016/j.amjcard.2020.06.028; Di Minno A, Lupoli R, Calcaterra I, Poggio P, Forte F, Spadarella G, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2020;9(15):e016262. https://doi.org/10.1161/jaha.119.016262; Thompson PD, MacDougall DE, Newton RS, Margulies JR, Hanselman JC, Orloff DG, et al. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016;10(3):556–67. https://doi.org/10.1016/j.jacl.2015.12.025; Gutierrez MJ, Rosenberg NL, Macdougall DE, Hanselman JC, Margulies JR, Strange P, et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014;34(3):676–83. https://doi.org/10.1161/atvbaha.113.302677; https://www.risksafety.ru/jour/article/view/385
-
3Academic Journal
Source: Лекарства Украины; № 2(258) (2022): приложение 1; 28-31
Medicine of Ukraine; No. 2(258) (2022): appendix 1; 28-31
Ліки України; № 2(258) (2022): додаток 1; 28-31Subject Terms: переносимость статинов, low-density lipoprotein cholesterol, эффективность лечения, артеріальний тиск, tolerability of statins, атеросклеротичні серцево-судинні захворювання, blood pressure, захворюваність, atherosclerotic cardiovascular diseases, холестерин ліпопротеїдів низької щільності, артериальное давление, 3. Good health, заболеваемость, treatment effectiveness, холестерин липопротеидов низкой плотности, ефективність лікування, incidence, переносимість статинів, атеросклеротические сердечно-сосудистые заболевания
File Description: application/pdf
Access URL: http://lu-journal.com.ua/article/view/264203
-
4Academic Journal
Authors: T. E. Kolmakova, I. A. Alekseeva, N. A. Tmoyan, M. V. Ezhov, Т. Е. Колмакова, И. А. Алексеева, Н. А. Тмоян, М. В. Ежов
Source: Aterotromboz = Atherothrombosis; № 2 (2021); 56-75 ; Атеротромбоз; № 2 (2021); 56-75 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2021-2
Subject Terms: COVID-19, low-density lipoprotein cholesterol (LDL-C), rosuvastatin, very high cardiovascular risk, extreme cardiovascular risk, холестерин липопротеидов низкой плотности (ХС ЛНП), розувастатин, очень высокий сердечно-сосудистый риск, экстремальный сердечно-сосудистый риск
File Description: application/pdf
Relation: https://www.aterotromboz.ru/jour/article/view/256/278; Шаповал И.Н., Никитина С.Ю. (ред.). Здравоохранение в России. Статистический сборник. М.; 2019. 170 с. Режим доступа: https://rosstat.gov.ru/storage/mediabank/Zdravoohran-2019.pdf.; Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. https://doi.org/10.1093/eurheartj/ehz455.; Кухарчук В.В., Ежов М.В., Сергиенко И.В., Арабидзе Г.Г., Бубнова М.Г., Балахонова Т.В. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020;1(38):7–40. Режим доступа: https://jad.noatero.ru/index.php/jad/article/view/274.; Ference B.A., Ginsberg H.N., Graham I., Ray K.K., Packard C.J., Bruckert E. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472. https://doi.org/10.1093/eurheartj/ehx144.; Колмакова Т.Е., Алексеева И.А., Ежов М.В. Розувастатин как доступное средство для эффективной профилактики сердечно-сосудистых заболеваний. РМЖ. 2020;10:20–24. Режим доступа: https://www.rmj.ru/articles/kardiologiya/Rozuvastatin_kak_dostupnoe_sredstvo_dlya_effektivnoy_profilaktiki_serdechno-sosudistyh_zabolevaniy/#ixzz6nO976Jge.; Catapano A.L., Graham I., De Backer G., Wiklund O., Chapman M.J., Drexel H. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2016;37(39):2999–3058. https://doi.org/10.1093/eurheartj/ehw272.; Алексеева И.А., Ежов М.В. Особенности применения фиксированной комбинации розувастатина и эзетимиба для эффективной гиполипидемической терапии. Медицинский совет. 2020;(14):26–32. https://doi.org/10.21518/2079-701X-2020-14-26-32.; Karlson B.W., Wiklund O., Palmer M.K., Nicholls S.J., Lundman P., Barter P.J. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur Heart J Cardiovasc Pharmacother. 2016;2(4):212–217. https://doi.org/10.1093/ehjcvp/pvw006.; Baygent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C. et al. Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278. https://doi.org/10.1016/S0140-6736(05)67394-1.; Luvai A., Mbagaya W., Hall A.S., Barth J.H. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol. 2012;6:17–33. https://doi.org/10.4137/CMC.S4324.; Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711–1718. https://doi.org/10.1001/jama.285.13.1711.; Cannon C.P., Braunwald E., McCabe C.H., Rade D.J., Rouleau J.L., Belder R. et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy – Thrombolysis in Myocardial Infarction 22 Investigators. N Engl J Med. 2004;350(15):1495–1504. https://doi.org/10.1056/NEJMoa040583.; Wiviott S.D., Cannon C.P., Morrow D.A., Ray K.K., Pfeffer M.A., Braunwald E. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46(8):1411–1416. https://doi.org/10.1016/j.jacc.2005.04.064.; Boekholdt S.M., Hovingh G.K., Mora S., Arsenault B.J., Amarenco P., Pedersen T.R. et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64(5):485– 494. https://doi.org/10.1016/j.jacc.2014.02.615.; Ray K.K., Cannon C.P., McCabe C.H., Cairns R., Tonkin A.M., Sacks F.M. et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005;46(8):1405–1410. https://doi.org/10.1016/j.jacc.2005.03.077.; Reiner Ž. Primary Prevention of Cardiovascular Disease with Statins in the Elderly. Curr Atheroscler Rep. 2014;16(7):420. https://doi.org/10.1007/s11883-014-0420-6.; McKenney J.M., Jones P.H., Adamczyk M.A., Cain V.A., Bryzinski B.S., Blasetto J.W. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin. 2003;19(8):689–698. https://doi.org/10.1185/030079903125002405.; Sexton T.R., Wallace E.L., Macaulay T.E., Charnigo R.J., Evangelista V., Campbell C.L. et al. The effect of rosuvastatin on thromboinflammation in the setting of acute coronary syndrome. J Thromb Thrombolysis. 2015;39(2):186–195. https://doi.org/10.1007/s11239-014-1142-x.; Maroo B.P., Lavie C.J., Milani R.V. Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike? Drugs Aging. 2008;25(8):649–664. https://doi.org/10.2165/00002512-200825080-00003.; Hall A.S., Jackson B.M., Farrin A.J., Efthymiou M., Barth J.H., Copeland J. et al. A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events – Reduction of Cholesterol to Key European Targets Trial. Eur J Cardiovasc Prev Rehabil. 2009;16(6):712–721. https://doi.org/10.1097/HJR.0b013e3283316ce8.; Lablanche J.M., Danchin N., Farnier M., Tedgui A., Vicaut E., Alonso J. et al. Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design. Arch Cardiovasc Dis. 2008;101(6):399–406. Available at: https://pubmed.ncbi.nlm.nih.gov/18809153.; Yun K.H., Jeong M.H., Oh S.K., Rhee S.J., Park E.M., Lee E.M. et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol. 2009;137:246–251. Available at: https://pubmed.ncbi.nlm.nih.gov/18706705.; Cay S., Cagirci G., Sen N., Balbay Y., Durmaz T., Aydogdu S. Prevention of Peri-procedural Myocardial Injury using a Single High Loading Dose of Rosuvastatin. Cardiovasc Drugs Ther. 2010;24(1):41–47. https://doi.org/10.1007/s10557-010-6224-1.; Ye Z., Lu H., Su Q., Guo W., Dai W., Li H. et al. Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in Chinese patients with acute coronary syndrome: A systematic review and meta-analysis. PLoS ONE. 2017;12(2):e0171682. https://doi.org/10.1371/journal.pone.0171682.; Guo J., Zhang W.Z., Zhao Q., Wo J.S., Cai S.L. Study on the effect of different doses of rosuvastatin on ventricular remodeling in patients with acute coronary syndrome after emergency percutaneous coronary intervention. Eur Rev Med Pharmacol Sci. 2017;21(19):4457–4463. https://pubmed.ncbi.nlm.nih.gov/29077146.; Toso A., Leoncini M., Maioli M., Tropeano F., Di Vincenzo E. , Villani S., Bellandi F. Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention). JACC Cardiovasc Interv. 2014;7(12):1421–1429. Available at: https://pubmed.ncbi.nlm.nih.gov/25523533.; Almeida S.O., Budoff M. Effect of statins on atherosclerotic plaque. Trends Cardiovasc Med. 2019;29(8):451–455. Available at: https://pubmed.ncbi.nlm.nih.gov/30642643.; Nicholls S.J., Ballantyne C.M., Barter P.J., Chapman M.J., Erbel R.M., Libby P. et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078–2087. https://doi.org/10.1056/NEJMoa1110874.; Nissen S.E., Tuzcu E.M., Schoenhagen P., Brown B.G., Ganz P., Vogel R.A. et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071–1080. https://doi.org/10.1001/jama.291.9.1071.; Kini A.S., Baber U., Kovacic J.C., Limaye A., Ali Z.A., Sweeny J. et al. Changes in Lipid Content After Short – Term Intensive Versus Standart StatinTherapy/ The YELLOW Trial (reductioninYellow Plaque by Aggressive Li pid-Lowering Therapy). J Am Coll Cardiol. 2013;62(1):21–29. https://doi.org/10.1016/j.jacc.2013.03.058.; Hong Y.J., Jeong M.H., Hachinohe D., Ahmed K., Choi Y.H., Cho S.H. et al. Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis. Circ J. 2011;75(2):398–406. https://doi.org/10.1253/circj.cj-10-0658.; Haddad R.M., Ballantyne C.M. METEOR Trial Reports on the Effect of Rosuvastatin on Progression of Carotid IntimaMedia Thickness in Low-Risk Individuals with Subclinical Atherosclerosis. Phys Sportsmed. 2010;38(2):180–182. https://doi.org/10.3810/psm.2010.06.1797.; Underhill H.R., Yuan C., Zhao X.Q., Kraiss L.W., Parker D.L., Saam T. et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonanceimaging trial. Am Heart J. 2008;155(3):584.e1–8. https://doi.org/10.1016/j.ahj.2007.11.018.; Kjekshus J., Apetrei E., Barrios V., Böhm M., Cleland J.G., Cornel J.H. et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248–2261. https://doi.org/10.1056/NEJMoa0706201.; Tavazzi L., Maggioni A.P., Marchioli R., Barlera S., Franzosi M.G., Latini R. et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231–1239. Available at: https://pubmed.ncbi.nlm.nih.gov/18757089.; Fellström B.C., Jardine A.G., Schmieder R.E., Holdaas H., Bannister K., Beutler J. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–1407. https://doi.org/10.1056/NEJMoa0810177.; Авдеев С.Н., Адамян Л.В., Алексеева Е.И., Багненко С.Ф., Баранов А.А., Баранова Н.Н. и др. Временные методические рекомендации Минздрава России. Профилактика. диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 10 (08.02.2021). М.; 2021. 262 с. Режим доступа: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/054/662/original/%D0%92%D1%80%D0%B5%D0%BC%D0%B5%D0%BD%D0%BD%D1%8B%D0%B5_%D0%9C%D0%A0_COVID-19_%28v.10%29.pdf.; Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Bethesda (MD): National Institutes of Health (US); 2021. Available at: https://pubmed.ncbi.nlm.nih.gov/34003615.; Bifulco M., Gazzerro P. Statins in coronavirus outbreak: it’s time for experimental and clinical studies. Pharmacol Res. 2020;156:104803. https://doi.org/10.1016/j.phrs.2020.104803.; Gupta A., Madhavan M.V., Sehgal K., Nair N., Mahajan S., Sehrawat T.S. et al. Extrapulmonary manifestations of COVID19. Nat Med. 2020;26(7):1017–1032. https://doi.org/10.1038/s41591-020-0968-3.; Zhang X.J., Qin J.J., Cheng X., Shen L., Zhao Y.C., Yuan Y. et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab. 2020;32(2):176–187.e4. https://doi.org/10.1016/j.cmet.2020.06.015.; Daniels L.B., Sitapati A.M., Zhang J., Zou J., Bui Q.M., Ren J. et al. Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients. Am J Cardiol. 2020;136:149–155. https://doi.org/10.1016/j.amjcard.2020.09.012.; Kow C.S., Hasan S.S. Meta-analysis of Effect of Statins in Patients with COVID-19. Am J Cardiol. 2020;134:153–155. https://doi.org/10.1016/j.amjcard.2020.08.004.; Hariyanto T.I., Kurniawan A. Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr. 2020;14(6):1613–1615. https://doi.org/10.1016/j.dsx.2020.08.023.; Iqbal Z., Ho J.H., Adam S., France M., Syed A., Neely D. et al. Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK. Atherosclerosis. 2020;313:126–136. https://doi.org/10.1016/j.atherosclerosis.2020.09.008.; Шальнова С.А., Деев А.Д., Метельская В.А., Евстифеева С.Е., Ротарь О.П., Жернакова Ю.В. и др. Информированность и особенности терапии статинами у лиц с различным сердечно-сосудистым риском: исследование ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2016;(4):29–37. https://doi.org/10.15829/1728-8800-2016-4-29-37.; Бойцов С.А., Якушин С.С., Марцевич С.Ю., Лукьянов М.М., Никулина Н.Н., Загребельный А.В. и др. Амбулаторно-поликлинический регистр кардиоваскулярных заболеваний в Рязанской области (РЕКВАЗА): основные задачи, опыт создания и первые результаты. Рациональная фармакотерапия в кардиологии. 2013;(1):4–14. https://doi.org/10.20996/1819-6446-2013-9-1-4-14.; https://www.aterotromboz.ru/jour/article/view/256
-
5
-
6
-
7
-
8Academic Journal
Authors: R. D. Kurbanov, N. U. Zakirov, Y. G. Kevorkova, N. B. Sayfiddinova
Source: Рациональная фармакотерапия в кардиологии, Vol 10, Iss 5, Pp 525-529 (2015)
Subject Terms: инфаркт миокарда, липиды, холестерин липопротеидов низкой плотности, печеночные трансаминазы, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701
File Description: electronic resource
-
9Academic Journal
Authors: Y. G. Kevorkova, N. U. Zakirov, N. B. Sayfiddinova, R. D. Kurbanov
Source: Рациональная фармакотерапия в кардиологии, Vol 10, Iss 5, Pp 525-529 (2015)
Subject Terms: lipids, low-density lipoprotein cholesterol, myocardial infarction, холестерин липопротеидов низкой плотности, RC666-701, liver transaminase, Diseases of the circulatory (Cardiovascular) system, Therapeutics. Pharmacology, RM1-950, инфаркт миокарда, липиды, печеночные трансаминазы, 3. Good health
Access URL: https://www.rpcardio.com/jour/article/download/212/222
https://doaj.org/article/fd6412141f294601b82b8f471b9865f8
https://doaj.org/article/ec0085e3dd0647709d3560237a3dfa3a
https://www.rpcardio.com/jour/article/view/212
https://core.ac.uk/display/44388770
https://www.rpcardio.com/jour/article/download/212/222 -
10Academic Journal
Authors: M. V. Ezhov, М. В. Ежов
Source: Meditsinskiy sovet = Medical Council; № 7 (2017); 5-10 ; Медицинский Совет; № 7 (2017); 5-10 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2017-7
Subject Terms: эволокумаб, atherosclerosis, hyperlipidemia, low-density lipoprotein cholesterol, evolokumab, атеросклероз, гиперлипидемия, холестерин липопротеидов низкой плотности
File Description: application/pdf
-
11Report
Subject Terms: low-density lipoprotein cholesterol, treatment compliance, статины, fixed combination of rosuvastatin and ezetimibe, холестерин липопротеидов низкой плотности, high and very high cardiovascular risk, высокий и очень высокий сердечно-сосудистый риск, 3. Good health, фиксированная комбинация розувастатина и эзетимиба, приверженность терапии, statins
-
12Report
Subject Terms: острый инфаркт миокарда, low-density lipoprotein cholesterol, lipid-lowering therapy, холестерин липопротеидов низкой плотности, дислипидемия, dyslipidemia, acute myocardial infarction, fixed combinations of statins and ezetimibe, липидснижающая терапия, 3. Good health, фиксированные комбинации статинов и эзетимиба
-
13Academic Journal
Authors: Юрий Александрович Карпов, Наталья Александровна Логунова, Юнона Владиславовна Хомицкая, Дарья Игоревна Томилова, Виталий Викторович Буза
Subject Terms: стенокардия напряжения, стенты с лекарственным покрытием, холестерин липопротеидов низкой плотности, приверженность терапии, чрескожное коронарное вмешательство, статины
File Description: text/html
-
14Academic Journal
Authors: СОРОКИН Е.В., КАРПОВ Ю.А.
File Description: text/html
-
15Academic Journal
Authors: Savchenko, Oksana Volodymyrivna
Subject Terms: rheumatoid arthritis, low-density lipoprotein cholesterol, ревматоїдний артрит, ґлюкокортикоїдний рецептор, ґлюкокортикоидный рецептор, ревматоидный артрит, ишемическая болезнь сердца, ischemic heart disease, холестерин ліпопротеїдів низької щільності, Bcl1 polymorphism, холестерин липопротеидов низкой плотности, glucocorticoid receptor, Bcl1 полиморфизм, ішемічна хвороба серця, Bcl1 поліморфізм
File Description: application/pdf
-
16Academic Journal
Authors: КАРПОВ Ю.А., ТАЛИЦКИЙ К.А.
File Description: text/html
-
17Academic Journal
Source: Атмосфера. Новости кардиологии.
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, ХОЛЕСТЕРИН ЛИПОПРОТЕИДОВ НИЗКОЙ ПЛОТНОСТИ,ГИПОЛИПИДЕМИЧЕСКИЕ ПРЕПАРАТЫ,ИНГИБИТОРЫ ПРОПРОТЕИНОВОЙ КОНВЕРТАЗЫ СУБТИЛИЗИН-КЕКСИНОВОГО ТИПА 9 (PCSK9)
File Description: text/html
-
18Academic Journal
Source: Атмосфера. Новости кардиологии.
File Description: text/html
-
19Academic Journal
Authors: Дедов, И., Шестакова, М., Александров, А., Галстян, Г., Григорян, О., Есаян, Р., Калашников, В., Кураева, Т., Липатов, Д., Майоров, А., Петеркова, В., Смирнова, О., Старостина, Е., Суркова, Е., Сухарева, О., Токмакова, А., Шамхалова, М., Ярек-мартынова, И.
File Description: text/html
-
20Academic Journal
